Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
about
Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older AdultsA cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.Evaluation of the Effectiveness of Pandemic Influenza A(H1N1) 2009 Vaccine Based on an Outbreak Investigation During the 2010-2011 Season in Korean Military CampsIdentification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Low expression of activation marker CD69 and chemokine receptors CCR5 and CXCR3 on memory T cells after 2009 H1N1 influenza A antigen stimulation in vitro following H1N1 vaccination of HIV-infected individualsComparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adultsImmunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients.Vaccination in elite athletes.Influenza vaccination for older adults.Milestones in history of adult vaccination in KoreaEffectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects.Traditional and new influenza vaccinesVaccine strategies to enhance immune responses in the aged.Mucosal adjuvants for influenza virus-like particle vaccine.Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice.
P2860
Q26783481-C62DC0B5-5C83-4956-8F87-45671F3D4327Q27009478-60AB6E6B-CCB3-4F5B-B077-0488F4391918Q30210342-11F7F209-AB79-4237-A3B6-5EC910EC38A9Q30354921-F6F4C07D-12B2-4942-BB6A-859F9704620BQ30371303-63C9DB55-2772-4132-900A-5CB757F5BBEEQ30375875-9C640096-44A9-4595-B224-EBEACD779D7CQ30413670-D6B60FA0-BDEB-45A2-AD36-C5BDD3094099Q30421428-A1AAE2CE-EE06-4641-BE40-F8C1B256B475Q34227424-03A33D0C-9A6B-4FC2-A2B2-A310B111AA63Q34247732-8C2F54C3-A94E-44BB-B100-D3808AF78732Q34340050-2590B8FD-E1B1-4753-BCE4-89847AE3AE01Q34805068-44F4D08C-4A4D-49BB-8EB3-3F942338A9CFQ35225020-511439B0-63A1-491E-A191-7DF5347FFE2CQ37035833-B06C6A1F-9F45-4720-975F-95E5EDC390C8Q37179398-FE91C545-9E54-4498-B4BC-D843DF283722Q37404044-5035756C-5CC3-4384-B148-A1F9D3695DDDQ46666851-C744309E-D870-4F12-9E6C-25B3B8513906
P2860
Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Immunogenicity and safety of t ...... versus nonadjuvanted vaccine.
@ast
Immunogenicity and safety of t ...... versus nonadjuvanted vaccine.
@en
type
label
Immunogenicity and safety of t ...... versus nonadjuvanted vaccine.
@ast
Immunogenicity and safety of t ...... versus nonadjuvanted vaccine.
@en
prefLabel
Immunogenicity and safety of t ...... versus nonadjuvanted vaccine.
@ast
Immunogenicity and safety of t ...... versus nonadjuvanted vaccine.
@en
P2093
P2860
P356
P1476
Immunogenicity and safety of t ...... versus nonadjuvanted vaccine.
@en
P2093
Dae Won Park
Hee Jin Cheong
Ji Yun Noh
Joon Young Song
Jung Yeon Heo
Seong-Heon Wie
Won Suk Choi
Woo Joo Kim
P2860
P304
P356
10.1128/CVI.05111-11
P577
2011-06-29T00:00:00Z